Memphasys (MEM.AX) ASX pre-market 25 Feb 2026: earnings due, what to watch

MEM.AX stock faces an earnings release on 26 Feb 2026 after trading at A$0.006 pre-market. We note a heavy intraday volume print of 18,263,359 shares and a market cap of A$17,083,380.00. The company has no reported EPS and trades with a wide valuation spread versus peers. Ahead of tomorrow’s update, investors should focus on revenue cadence, cash runway, and any commentary on commercial uptake of Felix and related devices.

Earnings outlook for MEM.AX stock

Memphasys reports on 26 Feb 2026 with an announced time of 10:59 UTC. We expect commentary on product sales, pilot programs, and R&D progress.

Key catalysts include reported unit sales of the Felix device and updates on SemPort and ROSA trials. Management guidance or timing on regulatory approvals will likely drive price action.

Financials and valuation

Memphasys shows tight liquidity and stretched margins. The price-to-sales ratio is 32.42 and price-to-book is 2.22.

Current ratio is 0.25 and debt-to-equity is 0.95, which suggest near-term funding sensitivity. Gross profit margin is 81.81%, but operating margin is negative at -4.87% and ROE is -86.37%. The company reports negative operating cash flow per share of -0.00121 and free cash flow per share equal to -0.00121.

Market reaction, liquidity and technicals

Pre-market liquidity is high by stock history with volume 18,263,359 and average volume 5,136,872. Year high is A$0.011 and year low A$0.003.

Technicals are neutral-to-mildly bearish: RSI 48.74, ADX 21.68, and a recent 50-day average of A$0.00594 versus a 200-day average of A$0.00465. Expect larger intraday swings on any surprise in the earnings.

Meyka AI grade and model forecast

Meyka AI rates MEM.AX with a score out of 100: 62.68 / 100 — Grade B, Suggestion: HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a near-term monthly price of A$0.01 and a one-year model price of A$0.00307. Versus the current A$0.006, the monthly projection implies +66.67% upside, while the one-year projection implies -48.89% downside. Forecasts are model-based projections and not guarantees.

Risks and opportunities in the Healthcare biotech sector

Opportunities include commercial adoption of Felix and export deals for SemPort. Success in trials could boost recurring consumable revenue.

Risks include limited cash runway, low current ratio, potential dilution, and the broader Healthcare sector weakness. The ASX Healthcare sector is down -2.21% today, which can amplify downside on negative news.

Trading strategy and price targets

We frame three scenario-based price targets for trading and risk management. A conservative bear target is A$0.003, a base case target is A$0.01, and a bull scenario target is A$0.02.

Short-term traders should size positions to volatility and watch volume on the release. Longer-term investors should insist on clearer revenue traction or funding visibility before adding exposure.

Final Thoughts

Key takeaways: MEM.AX stock trades at A$0.006 pre-market with earnings due on 26 Feb 2026. Liquidity is elevated at 18,263,359 shares and valuation metrics show stress in liquidity and profitability. Meyka AI’s forecast model projects a monthly price of A$0.01, implying +66.67% upside versus today’s price. The one-year model projects A$0.00307, implying -48.89% downside. Those divergent outcomes reflect the company’s binary clinical and commercial catalysts plus its tight balance sheet. We rate the setup as event-driven. Watch management’s operational metrics, cash commentary, and any pilot-to-commercial conversion figures. Meyka AI provides this as data-driven market analysis and not personal advice. Investors should size positions, use stop thresholds, and plan for volatility.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.